11X Stock Market Accelerator Summit

Eric Fry reveals how an A.I.-based secret could make you up to 11 times RICHER on the same stocks you’re investing in now… without using options, leverage, or anything risky.

Wed, September 27 at 8:00PM ET

3 Biotech Stocks to Sell in June Before They Crash and Burn


  • Here are three biotech stocks to sell in June before they crash and burn.
  • Regeneron Pharmaceuticals (REGN): Regeneron has fallen nearly 10% in the last month on demand concerns.
  • Moderna (MRNA): With sales of its Covid-19 vaccine dropping more than 70%, investors are asking: what’s next for Moderna?
  • Novavax (NVAX): Novavax was too late with its Covid-19 vaccine and recently had to cut its workforce by 25%.
biotech stocks to sell - 3 Biotech Stocks to Sell in June Before They Crash and Burn

Source: aslysun / Shutterstock.com

The biotechnology sector has seen better days. From the heady days of the pandemic when companies were racing to develop a vaccine against Covid-19, the industry is now enduring a hangover as both demand and sales decline. This means there’s more than a couple biotech stocks to sell. The iShares US Pharmaceuticals ETF (NYSEARCA:IHE) that tracks the industry is down 10% over the last 12 months and major players such as Pfizer (NYSE:PFE) have seen their share price decline 25% so far in 2023.

The downtrend continues, showing no signs of reversal. Investors should avoid the biotechnology sector for now. If already involved, it’s time to exit. Biotech and pharmaceutical makers face strong bearish sentiment. Here’s your guide to three biotech stocks. Sell them in June. Dodge the crash and burn.

Regeneron Pharmaceuticals (REGN)

pregnant woman visit gynecologist doctor at hospital or medical clinic for pregnancy consultant.
Source: Blue Planet Studio / Shutterstock.com

What little gains Regeneron Pharmaceuticals (NASDAQ:REGN) had achieved this year were largely wiped out over the past month as the company’s share price fell 8%. The brand is now up only 2% on the year and trending lower.

The stock did well during the pandemic when its antibody treatment was used to treat Covid-19, including in former President Donald Trump when he caught the respiratory disease.

The U.S. government propped up Regeneron. It spent billions on the company’s Covid-19 antiviral treatment. But now, those sales have dwindled. The stock price is falling. Regeneron still sells a popular vision-loss treatment, “Eylea,” and an eczema medication, “Dupixent”. However, its pipeline for potential new products looks thin. The Covid-19 sales have virtually evaporated. This makes the company one of those biotech stocks to sell.

Moderna (MRNA)

Moderna logo is seen at the entrance to its headquarters in Cambridge, Massachusetts. Moderna, Inc., (MRNA) is an American pharmaceutical and biotechnology company.
Source: Tada Images / Shutterstock.com

Another pandemic star whose fortunes have dimmed is Moderna (NASDAQ:MRNA). Year to date, Moderna is down 27%. The share price is now 70% lower than its all-time high of $450 reached in September 2021.

The stock skyrocketed during the pandemic as its Covid-19 vaccine was one of the first to be approved by the U.S. Food and Drug Administration (FDA). The company sold more than $18.4 billion of Covid-19 vaccines globally in 2022.

The company’s 2022 vaccine sales didn’t hit the projected $22 billion. The situation worsened with the Covid-19 vaccine sales forecast for 2023. It’s a mere $5 billion, a 73% drop from the previous year. This sent traders and investors scrambling to sell. MRNA stock went into a prolonged decline. Moderna’s other product line-up looks bleak. Its Covid-19 vaccine is the company’s only successful commercial product. This leaves investors questioning, “What’s next?”

Novavax (NVAX)

Novavax (NVAX) research laboratory logotype enlarged with a magnifying glass.This laboratory has developed a vaccine against the covid-19 virus. NVAX price predictions.
Source: pixinoo / Shutterstock.com

The last, and arguably worst, biotech stock that investors should consider selling in June before it crashes and burns is Novavax (NASDAQ:NVAX). The reality is that NVAX stock has already crashed and burned, having declined 83% over the past 12 months and now in danger of falling into penny stock territory. Sadly, it doesn’t appear that the share price has yet reached a bottom. As with the other names on this list, Novavax’s troubles stem from its focus on developing a treatment for Covid-19.

When the pandemic hit, Novavax pivoted from developing treatments for infectious diseases to developing a Covid-19 vaccine. However, repeated delays and problems cost the company dearly as its Covid-19 vaccine did not receive FDA approval until late last year. By then, the pandemic was in its final innings and Novavax was left to sell its treatment as a booster shot in developed countries and focus on sales to emerging nations in Africa and Asia. The company most recently reported revenue of only $81 million and cut 25% of its workforce.

On the date of publication, Joel Baglole did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Joel Baglole has been a business journalist for 20 years. He spent five years as a staff reporter at The Wall Street Journal, and has also written for The Washington Post and Toronto Star newspapers, as well as financial websites such as The Motley Fool and Investopedia.

Article printed from InvestorPlace Media, https://investorplace.com/2023/06/3-biotech-stocks-to-sell-in-june-before-they-crash-and-burn/.

©2023 InvestorPlace Media, LLC